We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Latest Posters

Ions for Mass Spec

Common Background Contamination Ions in Mass Spectrometry

With this poster, dive into the world of mass spectrometry troubleshooting, and discover detailed tables listing the accurate mass of elements, organic solvents and potential contaminant ions.
Bacteria Virus Microscope

Accelerating Antibody Discovery Using BLI Biosensor Technology

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.
Accelerate Drug Discovery With Chromatography

Accelerating Antibody Drug Development With Subdomain-Specific Affinity Chromatography

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.
Kinetic Analysis

Kinetic Analysis: Spotting the Weakest Binders

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.
Modeling Neurodegeneration

Discover a New Approach to Modeling Neurodegeneration

This poster demonstrates how a novel, precise and highly controlled iPSC reprogramming technology overcomes these limitations and enables the generation of mature cell types and isogenic models of neurodegenerative disease.

Optimized Human iPSC-Derived Sensory Neurons for Pain and Neuropathy Research

Many promising drugs which show efficacy in animal models have failed in the clinic due to interspecies variance in nociception mechanisms. Hence, consistent, scalable human in vitro models are required to accelerate potential therapeutics to the clinic.
Pure Neurons

Generating Pure, Consistent GABAergic Neurons From hiPSCs

While animal models and primary cells remain valuable resources, neuronal drug development faces many challenges. Not least, the variability and inaccuracy of traditional model systems can result in the failure to translate data into successful clinical trials.
Drug Targets

Accelerating the Discovery of Transmembrane Protein-Targeting Drugs

Drug discovery is a time-consuming, resource-intensive part of developing therapeutic targets. This is especially true for commonly considered 'undruggable' targets such as transmembrane proteins.
Achieving Powerful, Sustainable and Cost-Effective Sequencing  content piece image

Achieving Powerful, Sustainable and Cost-Effective Sequencing

Traditionally, there has been a compromise between performance and sustainability.

The NovaSeq X Plus system enables sequencing of >20,000 genomes per year and delivers data in half the time with a 2.5x improvement in throughput. Breakthrough advancement in chemistry, optics and software contribute to fast, highly accurate and cost-effective data.
Delivering Rapid, Accurate and Robust Sequencing content piece image

Delivering Rapid, Accurate and Robust Sequencing

Researchers looking to answer complex biological questions often require increased statistical power, larger studies and deeper sequencing methods.